The phase II clinical trial for the vaccine of the French-capital multinational Sanofi and the British GlaxoSmithKline (GSK) has just finished. The results seem encouraging: the companies have in fact reported that the adjuvanted recombinant COVID-19 vaccine candidate has achieved high immune responses.
The new vaccine challenge? The speed and spread of production
